SynCore Biotechnology Co.,Ltd (TPEX:4192)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
19.95
+0.10 (0.50%)
Apr 27, 2026, 2:31 PM CST
-32.49%
Market Cap 701.53M
Revenue (ttm) 27.04M
Net Income (ttm) -45.76M
Shares Out 35.16M
EPS (ttm) -1.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 238
Average Volume 10,436
Open 19.70
Previous Close 19.85
Day's Range 19.70 - 19.95
52-Week Range 19.25 - 30.35
Beta 0.35
RSI 42.19
Earnings Date May 12, 2026

About TPEX:4192

SynCore Biotechnology Co.,Ltd, engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the treatment of stomach cancer. It also offers SB03-Veregen, an ointment for the treatment of patients with external genital and perianal warts EGW; and SB04,... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 40
Stock Exchange Taipei Exchange
Ticker Symbol 4192
Full Company Profile

Financial Performance

In 2025, TPEX:4192's revenue was 27.04 million, an increase of 15.88% compared to the previous year's 23.34 million. Losses were -45.76 million, -15.71% less than in 2024.

Financial Statements

News

There is no news available yet.